Castle Biosciences to Release Third Quarter 2022 Financial Results and Host Conference Call on Wednesday, Nov. 2

Rhea-AI Summary

Castle Biosciences, Inc. (CSTL) will release its financial results for Q3 and the nine months ended Sept. 30, 2022, after market close on Nov. 2, 2022. The company will host a conference call at 4:30 p.m. Eastern time on the same day to discuss these results. Castle Biosciences focuses on innovative tests that guide patient care and has a portfolio that includes diagnostics for skin cancers and other conditions, with ongoing R&D for new tests targeting high clinical needs.

Positive

• Ongoing research and development for tests in high clinical need.
• Established diagnostics for various cancers and health conditions.

Negative

• None.

FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the third quarter and nine months ended Sept. 30, 2022, after the close of market on Wednesday, Nov. 2, 2022.

Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day.

Conference Call and Webcast Details

A live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/748805907 or via the webcast link on the Investor Relations page of the Company’s website, https://ir.castlebiosciences.com/overview/default.aspx. Please access the webcast at least 10 minutes before the conference call start time. A replay of the webcast will be available following the conclusion of the conference call.

To access the live conference call via phone, please dial 1 844 200 6205 from the United States, or +1 929 526 1599 internationally, at least 10 minutes prior to the start of the call, using the access code 723381.

There will be a brief Question & Answer session following management commentary.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221019005130/en/

Investor Contact:

Camilla Zuckero

czuckero@castlebiosciences.com

Media Contact:

Allison Marshall

amarshall@castlebiosciences.com

Source: Castle Biosciences, Inc.

FAQ

When will Castle Biosciences release its financial results for Q3 2022?

Castle Biosciences will release its financial results for Q3 2022 on November 2, 2022.

What time is the conference call for Castle Biosciences Q3 results?

The conference call for Castle Biosciences Q3 results will be held at 4:30 p.m. Eastern time on November 2, 2022.

What is the stock symbol for Castle Biosciences?

The stock symbol for Castle Biosciences is CSTL.

What is the focus of Castle Biosciences?

Castle Biosciences focuses on innovative tests that guide patient care.

What kind of tests does Castle Biosciences offer?

Castle Biosciences offers tests for skin cancers, uveal melanoma, Barrett’s esophagus, and mental health conditions.